Bortezomib in Kidney Transplantation

Although current therapies for pretransplant desensitization and treatment of antibody-mediated rejection (AMR) have had some success, they do not specifically deplete plasma cells that produce antihuman leukocyte antigen (HLA) antibodies. Bortezomib, a proteasome inhibitor approved for the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Raghavan, Rajeev, Jeroudi, Abdallah, Achkar, Katafan, Gaber, A. Osama, Patel, Samir J., Abdellatif, Abdul
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952895/
https://www.ncbi.nlm.nih.gov/pubmed/20953363
http://dx.doi.org/10.1155/2010/698594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952895/
https://www.ncbi.nlm.nih.gov/pubmed/20953363
http://dx.doi.org/10.1155/2010/698594

Ejemplares similares